Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F H WALTER

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Scientific Reports|October 30, 2020
Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesotheliomaSabrina Borchert, Pia-Maria Suckrau, Robert F H Walter, et al.
Cancers|April 30, 2021
Digital Gene Expression Analysis of Epithelioid and Sarcomatoid Mesothelioma Reveals Differences in ImmunogenicityLuka Brcic, Alexander Mathilakathu, Robert F H Walter, et al.
Cancer Management and Research|September 14, 2020
A Novel Epitope Quality-Based Immune Escape Mechanism Reveals Patient's Suitability for Immune Checkpoint InhibitionMichael Wessolly, Susann Stephan-Falkenau, Anna Streubel, et al.
Oncotarget|June 2, 2018
Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapyFabian D Mairinger, Jan Schmeller, Sabrina Borchert, et al.
BMC Cancer|February 1, 2019
Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitroSabrina Borchert, Michael Wessolly, Jan Schmeller, et al.
Journal of Oncology|August 17, 2018
Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53Robert F H Walter, Robert Werner, Michael Wessolly, et al.
European Journal of Cancer (Oxford, England : 1990)|October 15, 2020
Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression contextMarcel Wiesweg, Fabian Mairinger, Henning Reis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2021
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus TrametinibJan C Brase, Robert F H Walter, Alexander Savchenko, et al.
International Journal of Molecular Sciences|August 12, 2022
Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World SettingRamona Erber, Miriam Angeloni, Robert Stöhr, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Scientific Reports|October 30, 2020
Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesotheliomaSabrina Borchert, Pia-Maria Suckrau, Robert F H Walter, et al.
Cancers|April 30, 2021
Digital Gene Expression Analysis of Epithelioid and Sarcomatoid Mesothelioma Reveals Differences in ImmunogenicityLuka Brcic, Alexander Mathilakathu, Robert F H Walter, et al.
Cancer Management and Research|September 14, 2020
A Novel Epitope Quality-Based Immune Escape Mechanism Reveals Patient's Suitability for Immune Checkpoint InhibitionMichael Wessolly, Susann Stephan-Falkenau, Anna Streubel, et al.
Oncotarget|June 2, 2018
Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapyFabian D Mairinger, Jan Schmeller, Sabrina Borchert, et al.
BMC Cancer|February 1, 2019
Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitroSabrina Borchert, Michael Wessolly, Jan Schmeller, et al.
Journal of Oncology|August 17, 2018
Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53Robert F H Walter, Robert Werner, Michael Wessolly, et al.
European Journal of Cancer (Oxford, England : 1990)|October 15, 2020
Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression contextMarcel Wiesweg, Fabian Mairinger, Henning Reis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2021
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus TrametinibJan C Brase, Robert F H Walter, Alexander Savchenko, et al.
International Journal of Molecular Sciences|August 12, 2022
Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World SettingRamona Erber, Miriam Angeloni, Robert Stöhr, et al.
Pageof 2